



EFSA's Opinions on risks to health posed by BPA: methodological considerations

Paul Whaley

p.whaley@lancaster.ac.uk

ENSSER 2014


Berlin


11 Sept 2014



About me

- Environmental consultant working mainly with NGOs
- Interested in methods for improving processes for reviewing evidence in chemical risk assessment
- Report about how systematic review methods used in medicine could contribute to advancing the accuracy of chemical risk assessments
- BPA is a great case study of one aspect of what is going wrong with analysis of science behind policy-making







BPA Studies per year

Source: PubMed, search "bisphenol a"

■ Cumulative Count
■ Annual Count





Today's talk

- My analysis of EFSA's 2014 Draft Opinion on risks to health posed by bisphenol-A (BPA)

EFSA's Draft 2014 Scientific Opinion
on the risks to public health related
to the presence of bisphenol-A (BPA)
in foodstuffs: **a critical appraisal**

Paul Whaley
The Policy from Science Project
22 April 2014



Overview

- **Objective:** Evaluate the methodological quality of EFSA's reviews of risks to health posed by BPA
- **Method:** Develop a novel toolkit for appraising the methodological quality of literature reviews, derived from best practice in evidence-based medicine
- **Results:** EFSA risk assessments of BPA are either not conducted according to a scientifically robust methodology, or are insufficiently documented as to be able to determine one way or the other
- **Recommendation:** Develop systematic review tools for valid, reproducible synthesis of toxicological research in risk assessment

We are, through the media, as ordinary citizens, confronted daily with controversy and debate across a whole spectrum of public policy issues. But typically, we have no access to any form of systematic ‘evidence base’ — and therefore no means of participating in the debate in a mature and informed manner.

Prof. Sir Adrian Smith



Bisphenol-A: Who to believe?



How do you evaluate a review?

- What distinguishes a good review from a poor one?



Several toolkits in medicine

Critical
Appraisal
Skills
Programme

10 questions to help you

How to use this appraisal tool

Three broad issues need to be considered

- Are the results of the review valid?
- What are the results?
- Will the results help locally?

The 10 questions on the following pages are designed to help you appraise the evidence systematically.

The first two questions are screening questions. If the answer to either is "yes", it is worth proceeding with the appraisal.

There is some degree of overlap between the questions. A checklist designed to remind you why the questions are asked and the spaces provided.

There will not be time in the

NICE DSU TECHNICAL SUPPORT DOCUMENT 7: EVIDENCE SYNTHESIS OF TREATMENT EFFICACY IN DECISION MAKING: A REPORT BY THE D

REPORT BY THE D

AE Ades¹, Deborah M Caldwell¹, S

¹School of Social and Community
Whatley Road, Bristol BS8 2PS, UK
²National Institute for Health and
London, WC1V 6NA, UK
³Department of Health Sciences,
University Road, Leicester LE1 7RH, UK

BMC Medical Research Methodology

Research article

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Beverley J Shea^{*1,5}, Jeremy M Grimshaw^{†2}, George A Wells³, Maarten Boers^{†4},
Neil Andersson⁵, Candyce Hamel^{†5}, Ashley C Porter⁵, Peter Tugwell²,
David Moher⁶ and Lex M Bouter^{†1}

Address: ¹EMGO Institute, VU University Medical Center, Amsterdam, the Netherlands, ²Institute of Population Health, Ottawa, Ontario, Canada, ³Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada, ⁴Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, ⁵Community Information and Epidemiological Technologies (CIET/canada), Ottawa, Ontario, Canada and ⁶University of Ottawa, Ottawa, Ontario, Canada

Email: Beverley J Shea* - bshea@ciet.org; Jeremy M Grimshaw - jgrimshaw@ciet.ca; George A Wells - gwells@ottawaheart.ca; Maarten Boers - mboers@vumc.nl; Neil Andersson - nell@ciet.org; Candyce Hamel - chamel@uottawa.ca; Ashley C Porter - ashleycporter@hotmail.com; Peter Tugwell - ptugwell@uottawa.ca; David Moher - dmoher@uottawa.ca; Lex M Bouter - lmbouter@denst.vu.nl

* Corresponding author †Equal contributors

Published: 15 February 2007

BMC Medical Research Methodology 2007, 7:10 doi:10.1186/1471-2288-7-10
This article is available from: <http://www.biomedcentral.com/1471-2288/7/10>
© 2007 Shea et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 10 August 2006
Accepted: 15 February 2007

Abstract

Background: Our objective was to develop an instrument to assess the methodological quality of systematic reviews, building upon previous tools, empirical evidence and expert consensus.


Methods: A 37-item assessment tool was formed by combining 1) the enhanced Overview Quality Assessment Questionnaire (OQAQ 2) a checklist created by Sacks and 3) three additional items

Shortcomings of existing tools

- Incomplete in terms of targets of assessment
- Unclear rationale for targets of evaluation (e.g. use of at least two reviewers)
- Conflation of reporting with performance (something being done vs. it being done well)
- Lack of high-quality guidance notes or elicitation mechanisms to help users with appraisal
- Not intended for reviews in toxicology


New toolkit needed

- Developed from appraisal tools and best practice guidelines for conducting reviews in medicine
- e.g. CASP, PRISMA, NICE, AMSTAR and Cochrane Collaboration guidance on review methods (n=11)



So anyway, one year later ...


- **Literature Review Appraisal Toolkit (LRAT)**
- 9 evaluable domains relevant to the methodological quality of toxicological literature reviews



1. Clear objective




2. Prepub'd protocol



3. Interests & contribs




4. Search strategy



5. Selection criteria



6. External validity*




*test of relevance

7. Internal validity*





*test of reliability

8. Synthesis of data



9. Accurate summation






www.PolicyFromScience.com

/LRAT



Target of evaluation

- Utility (is the review useful?)
- Reproducibility (are the methods transparent?)
- Validity (are the results correct?)




1. Clear Objective

Is the review asking the right question?



2. Pre-published protocol

Prevents expectation bias



3. Declaration of interests

Allows review
objective and
findings to be put
in full context



4. Search strategy

Have all studies of possible relevance to review objective have been found?



(Helps preventing sampling bias)


5. Selection criteria

Have all studies of actual relevance to review objective included in analysis? (Helps prevent selection bias)



6. Fair test of *external validity**

*relevance



To consistently put more weight on the studies of greater direct relevance to the review objective

7. Fair test of *internal validity**


*reliability

To consistently put more weight on the better studies and less on the worse




8. Synthesis of evidence

Distillation of results into a valid statement of what is and is not known in relation to the review objective



9. Summation of findings



The summary sections of a review should reflect what is expressed in the body of the review

Appraisal options

Satisfactory


Clear, valid and consistent procedure

Unclear

Insufficient documentation to evaluate

Unsatisfactory

Positive evidence of inconsistent or invalid procedure



www.PolicyFromScience.com

/LRAT

EFSA 2014 Draft Opinion on BPA

1 **ENDORSED FOR PUBLIC CONSULTATION DRAFT SCIENTIFIC OPINION**

2 **Draft Scientific Opinion on the risks to public health related to the presence**
3 **of bisphenol A (BPA) in foodstuffs¹**

4 **EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids**
5 **(CEF)^{2,3}**

6 European Food Safety Authority (EFSA), Parma, Italy

7
8 **ABSTRACT**

9 EFSA asked its Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids to provide a
10 scientific opinion on the risks for public health related to exposure to bisphenol A from foodstuffs and other
11 sources. A two-step approach for public consultation on the draft opinion on BPA has been taken and a draft
assessment has previously been released for public consultation. The current draft addresses the hazard
of "likely" adverse effects in animals, i.e. on kidney, liver and
identification Benchmark dose

Parma, we have a problem

	EFSA 2014 Draft Opinion on BPA
1. Objective	●
2. Protocol	●
3. Interests	●
4. Search Method	●
5. Study Selection	●
6. Relevance Test	●
7. Reliability Test	●
8. Synthesis	●
9. Answer	●




1. Objective

Unclear



- The stated objective of the Opinion is to collate the published evidence of hazards to health posed by BPA and interpret this into a dose-based risk assessment
- However, the hazard characterization section redirects the Opinion towards determining whether or not any individual study exists which warrants changing the tolerable daily intake (TDI) for BPA.

2. Pre-published protocol



Unsatisfactory

- There is no pre-published protocol


3. Declaration of interests



Unclear

- Difficult to obtain
- Have to be extrapolated from lengthy DOIs
- No declaration of contributions


4. Search strategy



Unsatisfactory

- Literature search yields papers from 2010-2012 which are not referenced in the Opinion
- EFSA openly acknowledges partial search process for 2013 papers
- Unlike 2010, no list of search results!

Missing studies



- **Effects of prenatal and postnatal exposure to a low dose of bisphenol A on behaviour and memory in rats.** Gonçalves, Carjone Rosa; Cunha, Raquel Wigg; Barros, Daniela Marti; Martínez, Pablo Elías. Environmental Toxicology and Pharmacology, 2010
- **Anxiety- and Depressive-Like Behaviours in CD-1 Mice Developmentally Exposed to Bisphenol A.** Nelms, J; Ward, M; Meyer, A; Miller, M; Sable, H. Neurotoxicology And Teratology, 2011
- **The Effects of Maternal Exposure to Bisphenol A on Allergic Lung Inflammation into Adulthood.** Bauer, Stephen M; Roy, Anirban; Emo, Jason; Chapman, Timothy J; Georas, Steve N; Lawrence, B. Paige. Toxicological Sciences, 2012
- **Developmental exposure to bisphenol A leads to cardiometabolic dysfunction in adult mouse offspring.** Cagampang, F. R; Torrens, C; Anthony, F. W; Hanson, M. A. Journal of Developmental Origins of Health and Disease, 2012
- **The impact of neonatal bisphenol-A exposure on sexually dimorphic hypothalamic nuclei in the female rat.** Adewale, HB; Todd, KL; Mickens, JA; Patisaul, HB. Neurotoxicology, 2011
- **Corticosterone-regulated actions in the rat brain are affected by perinatal exposure to low dose of bisphenol A.** Poimenova A, Markaki E, Rahiotis C, Kitraki E. Neuroscience. 2010

5. Selection criteria



Unsatisfactory


- EFSA used a different selection process for including studies from 2013 (expert judgment of relevance to the review) than it did for studies from 2010-2012 (a specified list of inclusion criteria)

5.1 Furthermore ...



- EFSA changed its mind about the inclusion criteria for the 2014 Opinion
- At the point of hazard characterisation, it excluded the mammary epithelial cell proliferation studies for having “methodological shortcomings” which make them unsuitable for calculating a TDI
- Even though they were good enough to show a likely hazard!

6. External validity



Unclear

- No explicit methodology, though directness of evidence is sometimes described in the appraisal of research
- Not clear what the criteria for relevance are, nor how they affect the weight given to a study in the overall analysis, nor if they are consistently applied

7. Internal validity




Unsatisfactory

- Criteria for methodological quality are not valid
- Insufficient evidence that the criteria are consistently applied
- It is not clear how fulfilment of the criteria translates into a judgment of reliability

Comments on internal validity

- Conflates of quantity of information with quality of research (single dose studies downgraded)
- Consistency of findings between studies is taken as an indicator of methodological quality
- Conflates reporting quality with methodological quality
- Conflates conformity with guidelines with methodological quality
- Doesn't consider important aspects of methodological quality (e.g. random allocation)

8. Synthesis of evidence




Unclear

- Insufficiently documented
- Carefully documented but not at all clear how appraisal of studies is connected to attribution of weight in the WoE analysis

			Weight accorded to judgements				
			●	●/↑	↑	↑↑	↑↑↑
POSITIVE FINDINGS	Dev & Repro	Human	●●●●●●●●	●●			
		Animal	●●●	●●	●●	●	
	Neurotox	Human	●		●		
		Animal	●●●●●●●●●●●●	●●●●		●●	
	Immune	Human	●				
		Animal	●	●			
	Cardiovascular	Human	●●●●●	●			
	Metabolic	Human	●●●●●●●	●			
		Animal		●●●			
Genotoxicity	In vitro	●●		●		●●	
	Animal	●●●●		●			
Carcinogenicity	Animal	●●●	●●●				
			●	●/↓	↓	↓↓	↓↓↓
NEGATIVE FINDINGS	Dev & Repro	Human	●			●●	
		Animal					●●
	Neurotox	Human					
		Animal	●●●●	●●●●	●●		
	Immune	Human					
		Animal					
	Cardiovascular	Human					
	Metabolic	Human		●			
		Animal					●●
Genotoxicity	In vitro			●	●		
	Animal			●●	●●		
Carcinogenicity	Animal				●	●	

9. Summation of findings



Satisfactory

- Woopee!

Conclusions


- Search and selection methods are partial and risk biasing the results of the review
- The appraisal of methodological quality of included studies cannot distinguish better research from worse
- Weight-of-evidence analysis cannot be evaluated for validity
- EFSA has not actually conducted a coherent review of BPA toxicity, but instead only repeated its traditional TDI calculation, introduced by a lengthy but irrelevant hazard assessment

Analysis of EFSA Opinions on BPA

	2010 Opinion	2013 Draft Exp. Assessment	2014 Draft Opinion
1. Objective	●	●	●
2. Protocol	●	●	●
3. Interests	●	●	●
4. Search Method	●	●	●
5. Study Selection	●	●	●
6. Relevance Test	●	●	●
7. Reliability Test	●	●	●
8. Synthesis	●	●	●
9. Summation	●	●	●

**Science is supposed to be
cumulative, but scientists
only rarely cumulate
evidence scientifically.**

*Chalmers, Hedges &
Cooper (2002)*



We are, through the media, as ordinary citizens, confronted daily with controversy and debate across a whole spectrum of public policy issues. But typically, we have no access to any form of systematic ‘evidence base’ — and therefore no means of participating in the debate in a mature and informed manner.

Prof. Sir Adrian Smith




How to improve literature reviews

- Apply systematic review methods used in evidence-based medicine to chemical risk assessment




Research ♥ systematic review

- Manage data volume
- Cost-effective (because being wrong is expensive)
- ID knowledge gaps
- Know how far you can generalise
- Enhance credibility



Society ♥ systematic review

- Reduce harm to health & environment (accurate identification of risks)
- Reduce unnecessary economic costs (fewer false positives)
- Enhance credibility of institutions (produce readable, credible documents)



Democracy ♥ systematic review

- Access to systematic evidence-base rather than simply having to take on trust the pronouncements of experts
- Allows informed critique of policy options
- Participation in evidence-based decisions



Thank you

- Very
- Much
- Indeed
- Read my report
- Look at my website
- Research funding please, this is important